Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Polycythemia Vera 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

imetelstat 1Thalidomide 1Irinotecan 1GRN163L peptide 1Everolimus 1Dasatinib 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brain Stem Neoplasms × imetelstat × Clear all
NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Pediatric Brain Tumor Consortium

Phase 2 Terminated
43 enrolled 14 charts
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡